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temperature was 38.6C, her blood pressure was 140/80 mm Hg,
and her heart rate was 86 beats/min. The head and neck exami-
nation were significant only for mildly icteric sclera. The lungs
were clear to auscultation and percussion. The jugular veins were
not distended, and no murmurs, rubs, or gallops were heard.
Initial abdominal examination was notable for hypoactive bowel
sounds, although the abdomen was soft and non-tender to
palpation. Rectal examination revealed brown stool that was
4 positive for occult blood and later found to be positive for
fecal leukocytes. The neurologic examination was limited due
to the confused state of the patient, but it did not reveal any
focal defects.
Laboratory testing revealed: serum sodium, 135 mEq/L; po-
tassium, 3.4 mEq/L; chloride, 102 mEq/L; and bicarbonate,
19 mmol/L. The serum creatinine was 3.7 mg/dL; blood urea
CASE PRESENTATION nitrogen, 110 mg/dL; and total bilirubin, 4.2 mg/dL with normal
The patient, a 68-year-old white woman, presented to her hepatic transaminases. Hematocrit was 25% with a hemoglobin
primary physician with two to three days of bloody diarrhea; of 8.1 g/dL. The leukocyte count was 29,700/mm3 with 86%
bilateral, crampy, lower abdominal pain, and fever to 101F. polymorphonuclear cells, 3% bands, 8% lymphocytes, and 3%
Initially, she was treated with clear liquids as well as ciproflox- mononuclear cells. The platelet count was 49,000/mm3. Urinaly-
acin and loperamide. Over the next 24 hours, diarrhea, nausea, sis revealed a specific gravity of 1.011; pH 5; 2 protein, 2
and vomiting increased, causing her to go to the emergency blood, and 5 to 7 red blood cells/high-power field in the sedi-
ward. Her family had noted progressive confusion over the ment. No cellular casts were present. A chest radiograph was
previous 24 hours. There was no history of recent travel, nor unremarkable, and a KUB radiograph revealed an ileus with-
was there any known contact with infected individuals. Her
out evidence of free air.dietary history was significant for the ingestion of hamburger
Over the following 12 hours, the patient’s abdominal exami-meat three days prior to the onset of symptoms. She had had
nation changed, with the development of overt peritoneal signstype II diabetes mellitus for eight years, hypertension for 25
leading to an exploratory laparotomy. Extensive edema of theyears, and hypothyroidism. Her medications on admission were
distal ileum and colon with evidence of infarction was found.hydrochlorothiazide, 25 mg/day; metoprolol, 25 mg twice daily;
A partial colectomy, partial ileal resection, and ileostomy wereand thyroxine in addition to the ciprofloxacin and loperamide.
performed. Pathology of the colon revealed extensive bowelThere was no family history of renal or hematologic disease.
wall edema with regions of infarction, sloughing of mucosa,A retired secretary who lived alone, she was too confused to
and local microangiopathy. The bowel had marked infiltration ofgive a review of systems, although her family stated that prior
to this acute illness she had been doing well. polymorphonuclear cells with crypt abscesses. Her postoperative
Physical examination in the emergency ward revealed a mark- course was complicated by oliguria and rapidly worsening renal
edly confused woman unable to state her name or the date. Her function. Hemodialysis was initiated. She was treated with
broad-spectrum antibiotics and underwent a total of six plasma
exchange treatments using fresh frozen plasma as the replace-
The Nephrology Forum is funded in part by grants from Amgen, ment fluid. A stool culture from her initial visit with her primary
Incorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo- physician grew Escherichia coli O157:H7. Her hospital course
rated; and Bristol-Myers Squibb Company.
was prolonged (4 months total) and complicated by adult respi-
ratory distress syndrome (ARDS), pancreatitis, seizures, Clos-Key words: Shiga toxin, enterohemorrhagic E. coli, von Willebrand
factor-cleaving protease, hemorrhagic enterocolitis, thrombotic mi- tridium difficile colitis, and Staphylococcus aureus bacteremia.
croangiopathy. She never regained renal function, but her mental status re-
turned to normal. 2002 by the International Society of Nephrology
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DISCUSSION Shiga toxin-producing Escherichia coli
Shiga toxin (Stx)-producing Escherichia coli has beenDr. Andrew J. King (Division Head, Division of Ne-
phrology, Scripps Clinic and Green Hospital, La Jolla, designated by the U.S. Centers for Disease Control and
Prevention as an “emerging pathogen” [6]. As manyCalifornia, USA): This unfortunate woman provides a
dramatic illustration of the devastating nature of adult as 90% of children with HUS have antecedent STEC,
typically of the serotype O157:H7 [7]. The association ofhemolytic-uremic syndrome (HUS) induced by entero-
hemorrhagic Escherichia coli (EHEC). She had multi- Shiga toxin-producing Shigella dysenteriae with HUS was
first made by Koster et al in 1978 [8], followed by obser-organ involvement, including the gut, central nervous
system, and kidney, a presentation not too divergent vations indicating an association of E. coli cytotoxins
with the syndrome by Karmali et al in 1985 [9]. Thefrom the patient with thrombotic microangiopathy first
described by Eli Moschowitz in 1924 [1]. Thrombotic implicated E. coli cytotoxins, Stx1 and Stx2, belong to a
family of bacterial protein toxins related to the parentmicroangiopathy (TMA) is a term applied to a group of
disorders that present with thrombocytopenia, evidence Shiga toxin, which share the same enzymatic action and
recognize related host-neutral glycolipid receptors. In-of red blood cell destruction, and a characteristic patho-
logic appearance in the microvasculature, including en- terest in this disease has been fostered by considerable
media attention stemming from several notable out-dothelial cell injury and platelet deposition. Thrombotic
microangiopathy is associated with a wide range of infec- breaks, including one in 1993 related to undercooked
hamburgers at “Jack in the Box” restaurants in the north-tions, drugs, tumors, and other disorders. The focus of
west United States and one more recently in Japan. De-this report, however, is HUS triggered by EHEC. First
pending on the outbreak, patients with documenteddescribed by Gasser et al in 1955 [2], HUS is a term
STEC have a risk of developing HUS of approximatelyapplied to a TMA with predominant renal involvement.
5% to 10% [7]. Details regarding the genetics, regulation,Although there had been speculation that HUS and
structure, enzymatic specificity, and physiology of thethrombotic thrombocytopenic purpura (TTP) were dif-
Stx family are found in several reviews [10–12]. Briefly,fering manifestations of the same disease, it recently has
Stx is a heterodimer consisting of an enzymatically activebecome clear that for the majority of adults with TTP,
A subunit surrounded by five identical B subunits. Thethe key pathologic feature is an immunoglobulin that
receptor for the toxin is a blood group active glycolipid,inactivates circulating von Willebrand factor (vWF)-
globotriaosylceramide (Gb3). The distribution and fattycleaving protease [3, 4]. Failure to properly metabolize
acid chain composition of Gb3 are believed to play anaturally occurring ultralarge multimers of vWF leads
role in susceptibility of various cells to the toxin [13].to increased binding to platelet glycoproteins under con-
Upon binding, internalization and activation of the Aditions of high shear stress, that is, that which exists in
subunit lead to depurination of a specific adenosine inthe microvasculature. These features of TTP explain the
28S ribosomal RNA; the end result is irreversible inhibi-remarkable efficacy of plasma exchange in this disorder
tion of protein elongation [14]. Glomerular endothelial[5]. By contrast, vWF-cleaving protease activity is nor-
cells and, to a greater extent, renal tubular epithelial cells,mal in patients with HUS, and the efficacy of plasma
express Gb3, thereby contributing to the propensity of pa-exchange is much less clear.
tients infected with STEC to develop acute renal failure.Unlike TTP, patients with diarrhea-induced HUS have
abundant evidence of an acute inflammatory response,
Clinical markers of acute inflammationthe magnitude of which predicts clinical outcome. In this
Forum, I will review evidence suggesting that inflamma- The woman presented today had high fever and marked
leukocytosis, common findings in patients presenting withtory cells and their byproducts play a major role in (1)
loss of intestinal barrier function, thereby promoting STEC. Leukocytosis can be extreme, as in leukemoid
reactions, and it is a positive predictor of acute mortalitymovement of endotoxin and Shiga toxins into the circula-
tion; (2) delivery of Shiga toxins to target organs; (3) and residual nephropathy [15–18]. Children with “diar-
rhea-positive” HUS (DHUS) have significantly highersensitization of target organs to Shiga toxins by increas-
ing glycolipid receptor expression; and (4) direct injury leukocyte counts on presentation than do children with
atypical “diarrhea-negative” HUS (D-HUS); this findingof target organ endothelium. Although definitive evi-
dence for a role of inflammatory cells and their mediators suggests that the intestinal disease is an important factor
in generating the leukocytosis [15]. In the Osaka out-is lacking in humans, on circumstantial evidence, the
case is compelling. Patients with HUS due to Shiga toxin- break of 1996, both leukocyte count and C-reactive pro-
tein were higher in the group of children with STECproducing Escherichia coli (STEC) rarely present in the
first 24 to 48 hours and thus, as with other forms of acute who developed HUS compared to infected children who
did not [19]. Severe gastrointestinal disease also portendsrenal failure (ARF), we are left looking for the “smoking
gun,” the mediators that cause the ARF. a poor prognosis in children with STEC.
Nephrology Forum: Inflammation and HUS 1555
Fig. 1. Potential role of resident and circulating inflammatory cells in Shiga toxin-producing Escherichia coli (STEC)-induced enterocolitis.
Abbreviations are: Stx, Shiga toxin; LPS, lipopolysaccharide; M, macrophages; ROI, reactive oxygen intermediates.
Role of inflammatory cells in hesion molecule CD-18 prevented intestinal infiltration
hemorrhagic enterocolitis of PMN and rendered histologic and functional protec-
tion [25].The gastrointestinal disease in patients with STEC
Shiga toxin traverses polarized intestinal human epi-varies from watery diarrhea to the most severe form,
thelial cells grown in tissue culture and retains biologichemorrhagic colitis. Colonic inflammation might play a
activity [26]. Recent evidence suggests that Stx inducesrole in local intestinal microangiopathy, the transfer of
a chemokine response from human intestinal epithelialStx from the bowel lumen through the lamina propria
cells [27]. Using a human colonic epithelial cell line, Stxand into the circulation, and the generation of a systemic
treatment led to “superinduction” of interleukin-8 (IL-8)inflammatory response (Fig. 1). Although STEC was not
with increase in both IL-8 mRNA and protein, the latterpreviously thought to provoke marked intestinal in-
occurring despite the known inhibitory effects of Stx onflammation, Slutsker et al noted that patients with STEC
protein elongation [27]. Secretion of IL-8 into the laminafrequently have fecal leukocytes [20]. Indeed, colonic
propria might create a chemokine gradient sufficient tobiopsy specimens from patients with STEC often have
recruit circulating PMNs. Both IL-8 and tumor necrosiscrypt abscesses and infiltrates of monocytes and poly-
factor- (TNF-) are more elevated in stools of patientsmorphonuclear cells (PMNs) [21–23]. In rabbits, infec-
with Stx-producing S. dysenteriae compared to patientstion with E. coli O157:H7 leads to severe inflammatory
infected with non-Stx-producing S. flexneri [28]. Severalcolitis with PMN infiltrates [24]. In this model, infusion
of monoclonal antibodies directed toward the PMN ad- investigators have found that patients with STEC-induced
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Table 1. Blood and urinary cytokines in HUS
Cytokine Levels References
IL-8 Blood Increased [18, 29-33, 35]
Urine Increased [33]
TNF- Blood Increased [36]
Unchanged or infrequent [18, 34, 35, 37]
Urine No or scant data
IL-1 Blood Increased [35]
Unchanged or infrequent [37]
Urine No or scant data
IL-6 Blood Increased [30-32, 34, 37, 38]
Unchanged or infrequent [35]
Urine Increased [34]
IL-10 Blood Increased [30-32]
Decreased [29]
Fig. 2. Indirect immunofluorescence assay of Stx-2 bound to polymor-Urine No or scant data
phonuclear cells (PMNs) in a patient presenting with hemolytic-uremic
syndrome (HUS). Reprinted with permission from the American Soci-
ety of Nephrology [45].
HUS have elevated circulating levels and urinary excre-
tion of IL-8 (Table 1). The magnitude of IL-8 elevation
ated with high circulating levels of IL-1 and TNF-.correlates with markers of PMN degranulation and with
Increases in circulating inflammatory cytokines likely arepatient outcome [18]. Other potential intestinal sources
triggered by the colonic infection and possibly by theof chemokine production are the resident and influxing
low-grade endotoxemia (Table 1). When assessing theleukocytes in the lamina propria. Murine macrophages
degree of cytokine elevation, note that renal failure inde-exposed to Stx increase production of both TNF- and
pendently contributes to high levels [49]. Futhermore,IL-6 [39]. Van Setten et al have shown in human mono-
patients with uncomplicated STEC also have increasedcytes that Stx increases production of IL-1, TNF-, IL-
levels. Despite these caveats, it appears that patients with6, and IL-8 and does not inhibit protein synthesis [40].
HUS have elevated circulating inflammatory cytokines. IBinding sites for Stx on the monocytes were increased
will discuss the role of these cytokines as possible “co-with lipopolysaccharide exposure. By contrast, Rameg-
conspirators” in vascular injury in a few moments. How-owda and Tesh found that human monocytes and mono-
ever, local production of cytokines in the gut wall mightcytic cell lines were quite resistant to Stx unless the cells
be an important second step in the generation of intesti-were pretreated with phorbol esters [41].
nal inflammation because of their ability to activate intes-Several potential consequences of a local inflamma-
tinal endothelial cells, thereby increasing adhesion mole-tory response in the lamina propria exist. Transepithelial
cule expression and PMN diapedesis.migration of PMNs can lead to transient loss of colonic
barrier function and cause the passage of luminal con- Direct effects of Shiga toxins on inflammatory cells
tents into the circulation [42, 43]. In one recent study,
Increasing evidence, both in vitro and in vivo, suggestsmovement of PMNs from the basolateral to the apical
that Stx binds to PMN, triggers PMN activation, andside of a human intestinal epithelial cell line allows in-
promotes adherence of PMNs to target endothelium. Tecreasing translocation of both Stx1 and Stx2 in the oppo-
Loo et al recently found that Stx binds to PMNs (notsite direction [44]. Loss of barrier function could contrib-
via Gb3) and raised the possibility that these cells areute to direct entry of Stx into the circulation, as well as
direct carriers of the toxin from the gut to target organsendotoxemia that would promote a systemic cytokine
[50]. Further, these investigators report that circulatingresponse. To date, no one has been able to detect circu-
PMNs and, to a lesser extent monocytes from patientslating Stx in patients with STEC. Recent studies, how-
with DHUS, have Stx bound to the surface (Fig. 2) [45].ever, have revealed Stx bound to circulating PMNs in
As I said before, these data demonstrated unequivocallypatients with DHUS, thus confirming entry into the
that Stx penetrates the gut in STEC-induced HUS andcirculation [45]. Most cellular responses in vitro, how-
suggest that PMNs transport Stx to target cells. Activatedever, are elicited at Stx doses well below the lower limits
PMNs contribute to tissue injury by releasing proteolyticof detection in plasma. Sepsis syndrome is very uncom-
enzymes, reactive oxygen intermediates, and phospho-mon in children with STEC, except in the setting of
lipid derivatives. Fitzpatrick et al detected in childrenbowel infarction. In this regard, several investigators
with DHUS sustained increases in 1-antitrypsin-com-have found specific antibodies to the lipopolysaccharide
plexed elastase, a PMN degranulation product thatof Stx-producing E. coli [46–48]. Endotoxemia is much
peaked approximately 3 to 4 days into admission [18].more prominent in patients with S. dysenteriae, an infec-
tion that is more likely to cause HUS and which is associ- Interestingly, this rise was preceded by an increase in
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Fig. 3. Renal injury in patients with STEC proceeding from normal (top) to overt HUS (bottom). RTE, renal tubular epithelium; RBC, red blood
cell; TNF, tumor necrosis factor; IL-1, interleukin-1; Gb3, globotriaosylceramide; GEC, glomerular endothelial cell; GepC, glomerular epithelial
cell; PMN, polymorphonuclear cell; mes cell, mesangial cell.
IL-8, a chemokine that also activates PMNs. Others have or to undergo phagocytosis. Noris et al noted an approxi-
mate twofold increase in superoxide release of PMNsconfirmed the increase in elastase but were unable to
detect activation of peripheral blood PMNs using chemi- isolated from adults with recurrent TMA compared to
controls [54]. These investigators also noted higherluminescence to assess for oxidative burst [51].
Evidence exists that children with HUS are under oxi- plasma nitrite/nitrate levels, a rise indicative of increased
production of another reactive oxygen species, nitric ox-dative stress. Malonyldialdehyde blood levels are in-
creased and there is oxidative damage to erythrocytes ide (NO). The source of NO remained speculative, al-
though it was observed that the serum of patients with[52–55]. Patients with acute renal failure from other
causes, however, also are under oxidative stress, and TMA induced higher levels of NO production from re-
porter human umbilical vein endothelial cells (HUVEC)the clinical literature on HUS in general rarely includes
appropriate controls. We have shown that Stx induces compared to control serum [54].
The question remains open as to whether toxin-stimu-release of superoxide from PMNs in vitro in a dose-
dependent fashion and suggested that the toxin directly lated PMNs actually contribute to tissue injury, either
in the gut or in remote target organs. The first evidencetriggers oxidative burst in PMNs (Fig. 3) [56]. These cells
were subsequently less able to respond to phorbol esters supporting this possibility came from Forsyth et al, who
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noted that PMNs isolated from children with diarrhea- Potential role of inflammation on target organ injury
induced HUS are more adherent to reporter HUVEC Whereas inflammatory cells are abundant in the gut
than are control PMNs [57]. Further, these PMNs in- of patients with STEC-induced HUS, their presence is
duced morphologic evidence of endothelial cell injury far more subtle in the primary target organs, the central
in the form of fibronectin breakdown, an effect that was nervous system, and the kidney. In a case control study
blocked in a subset of the patients by a CD-18 antibody. of 15 autopsy specimens from children who died during
Our laboratory has examined this issue in vitro using a the acute phase of DHUS, however, the median num-
co-culture model, whereby normal PMNs are stimulated ber of PMNs per 100 glomeruli was 929 compared to
by Stx and placed in co-culture with reporter human 156 for controls (children who died with normal renal
saphenous vein endothelial cells (SVEC) (abstract, Mur- function) [61]. The median peripheral neutrophil count
in this autopsy series was 21  109/L. Although animalray SL et al, J Am Soc Nephrol 10:533A, 1999). We dem-
models have been problematic in the study of this dis-onstrated that Stx-stimulated PMNs induced apoptosis
ease, a naturally occurring disease in the greyhound dog,in the co-cultured SVEC, whereas untreated PMNs or Stx
“Greentrack disease” (a.k.a. “Alabama rot”), bears aalone did not. Other investigators have confirmed human
striking resemblance to the human disease; in this model,microvascular endothelial cell cytotoxicity of PMNs from
PMNs are present in the glomerulus [62]. In a recentlypatients with TMA, noting significant protection by a
described rat model of HUS induced by ricin, a toxinmetalloprotease inhibitor (BB3103), and several reac-
with similar ribotoxic effects to Stx, all the features seentive oxygen species inhibitors (abstract, Ruiz-Torres et al,
in human HUS exist, including glomerular thrombosisJ Am Soc Nephrol 11:506A, 2000). Taken together, these
and injury [63]. The glomeruli of these rats had a substan-results suggest that Stx-stimulated PMNs in the lamina
tial increase in glomerular macrophages within eightpropria (resident and recruited) contribute to endothe-
hours of ricin infusion and increased circulating mono-lial cell damage in the intestine and lead to hemorrhage,
cyte chemotactic protein-1, TNF-, IL-1, and IL-6. Theloss of barrier function, and local microangiopathy. Thorpe
recent finding by te Loo et al increases the likelihoodet al also have shown that human intestinal microvascu-
that PMNs are an important carrier of Stx to the targetlar endothelial cells express high levels of Gb3 and are
endothelium [45]. The number of Stx-positive cellsexquisitely sensitive to the ribotoxic effects of Stx1 and
dropped off dramatically after 3 to 5 days in the patients2 [27]. Whether Stx-activated PMNs act on target organs
with sequential measurements. Although the fate ofis an intriguing question that I will discuss later.
those Stx-laden PMNs is unclear, it was shown convinc-The findings of Forsyth et al that PMNs from patients
ingly that transfer of toxin occurs from the as-yet-unde-with TMA are more adherent to endothelial cells raises
fined PMN binding site to Gb3 on glomerular endothelialthe possibility that Stx might alter adhesion molecular
cells in vitro [50].
expression [57]. Indeed, Morigi and colleagues found
By definition, the kidney is the primary target organ
that Stx1 pretreatment of HUVEC increased the binding
in STEC-induced HUS. This vulnerability is in large part
of leukocytes flowing across the endothelial monolayer due to the high density of Gb3 receptors in the renal
in a dose-dependent fashion [58]. The magnitude of ef- microvasculature and renal tubular epithelial cells [64].
fect was comparable to IL-1 and was inhibited by mono- Indeed, renal tubular epithelial cells are perhaps the
clonal antibodies to various adhesion molecules (E-selec- richest cellular source of Gb3 yet identified, equaling or
tin, ICAM-1, and VCAM). Further, TNF- together with perhaps even exceeding that of Vero cells. The open
Stx led to greater binding than with either TNF- or Stx question is how much this vulnerability is due to ambient
alone. In preliminary studies, we have observed that cytokine effects (Table 2). The laboratory of Hughes et
flowing PMNs treated with Stx bind better to untreated al [67] and our laboratory have shown that these cells
HUVEC than do vehicle-treated PMNs, an effect that are exquisitely sensitive to the ribotoxic effects of Stx;
is magnified by pretreatment of HUVEC with IL-1 (per- this work raises the possibility that acute tubular necrosis
sonal observations). In the acute phase of DHUS, solu- plays a role in the renal failure (abstract, King et al,
ble VCAM levels are increased [59, 60]. Once again, the J Am Soc Nephrol 9:580A, 1998). Human glomerular
effects of acute renal failure per se might play a role, as microvascular endothelial cells (GMEC) express lesser
VCAM levels in the HUS patients were lower than in amounts of Gb3, and in our studies and those of van
dialyzed controls without HUS [59]. Our ability to detect Setten et al [72], GMEC were less sensitive to the ribo-
endothelial cell activation in vivo is limited. Neverthe- toxic effects of Stx than were other microvascular endo-
less, these in vitro studies do support the possibility that thelial cells, such as human intestinal or foreskin endo-
increased levels of pro-inflammatory cytokines have an thelial cells. The variation in the literature with respect
accelerant effect on the binding of toxin-laden PMNs to to human GMEC sensitivity is likely due to differences
in source of cells, method of isolation, culture conditions,target endothelium.
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Table 2. Effects of cytokines on human kidney cell sensitivity to Stx
Cell Cytokine Gb3 density/binding Ribotoxicity Apoptosis Reference
Glomerular endothelium
TNF- Increased density Increased ND [40]
TNF- ND ND Induceda [65]
TNF- No change No change ND [64]
LPS No change No change ND
Glomerular epithelium
IL-1 Increase Increase ND [66]
TNF- Increase Increase ND
IL-6 No change No change ND
LPS Increase Increase ND
Mesangium
IL-1 ND Increase ND [68]
TNF- ND Increase ND
Renal tubular epithelium
Proximal tubules IL-1 Increased binding Increase ND [67]
TNF- No change No change ND
IL-6 No change No change ND
LPS No change Increase ND
Proximal tubules TNF- ND ND Increased [69]
Cortical cells TNF- ND ND Increased [70]
ACHN cell line TNF- ND ND Increased [71]
ND, not done.
a Apoptosis required pretreatment with TNF-
and inter-human variability (perhaps related to Gb3 fatty vulnerability to undergo apoptosis. If the finding that Stx
increases adhesion molecule expression holds true foracid chain variance). Pretreatment of GMEC with TNF-
substantially increased both receptor density and sensi- human GMEC, this mechanism could serve as an acceler-
ant to glomerular injury by increasing Stx delivery.tivity to Stx [72]. In keeping with these findings, recent
data suggest that Stx induces apoptosis of GMEC only
Conclusionif cells are pretreated with TNF- [65]. Taken together,
these data suggest that the magnitude of cytokine re- Shiga toxin-producing Escherichia coli is an “emerging
sponse determines the expression of the glomerular dis- pathogen” that causes a devastating systemic disease,
ease. However, investigators who have carefully mea- hemolytic-uremic syndrome. The gastrointestinal dis-
sured levels of inflammatory cytokines have shown an ease is associated with fecal leukocytes and a robust
inconsistent relationship with disease severity, particu- inflammatory response in the intestinal lamina propria.
larly when appropriate controls are included, such as Shiga toxin itself likely triggers chemokine production by
patients with uncomplicated STEC or other causes of intestinal epithelial cells and/or resident macrophages,
renal failure (Table 1). Other possible sources of in- which leads to the influx of circulating inflammatory cells
flammatory cytokines include activated monocytes ad- into the lamina propria. Once established, the local in-
herent to glomerular cells or kidney cells. In support of flammation could promote injury both to the intestinal
the latter possibility, Stx infusion into transgenic mice epithelium and endothelium and lead to intestinal hem-
bearing a chloramphenacol acetyl transferase (CAT) orrhage, loss of barrier function, and generation of in-
gene indicative of TNF- synthesis revealed increased flammatory cytokines. Loss of barrier function allows
CAT activity exclusively in the kidney [73]. Furthermore, Stx to penetrate into the circulation, where it circulates
renal levels of TNF-, IL-1, and IL-6 are increased in freely or bound to PMN and is delivered to target organs.
gnotobiotic mice inoculated with E. coli O157:H7 [74]. Injury of target cells is promoted by increased ambient
Hughes and colleagues make a strong case for renal inflammatory cytokines, possibly as a result of increased
tubular epithelial cells as a possible source of local cyto- receptor density, and it culminates in organ dysfunction.
kine production [67]. They demonstrated potent induc- The excessive vulnerability of the glomerulus likely re-
lates to direct contact with toxin-loaded PMNs and istion and release of TNF- and IL-1 from non-trans-
formed human proximal tubule cells exposed to Stx, potentially increased by high local concentrations of pro-
inflammatory cytokines generated by renal tubular epi-effects that were magnified by lipopolysaccharide. Taken
together, these data suggest that inflammatory cytokines thelial cells. The fact that toxin-loaded PMNs are present
when the patient is admitted to the hospital raises thecontribute to glomerular injury by increasing Gb3 ex-
pression on GMEC, thereby heightening the sensitivity possibility that leukopheresis might be a therapeutic op-
tion that will reduce target organ injury.of these cells to the ribotoxic effects of Stx and their
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QUESTIONS AND ANSWERS recurrent HUS who would become anuric whenever she
acquired an infection with a fever greater than 101F.Dr. Nicolaos E. Madias (Executive Academic Dean,
Whatever the insult is to the endothelium, three manifes-Tufts University School of Medicine, Boston, Massachu-
tations of this injury are the loss of the non-thrombogenicsetts): You mentioned that approximately 5% to 10% of
properties of the monolayer, exposure of the basementchildren with documented Shiga toxin producing E. coli
membrane, and platelet aggregation, all of which leaddevelop HUS. In view of the importance of pro-inflam-
to a characteristic pathologic finding.matory cytokines in the pathogenesis of the syndrome,
Dr. Andrew S. Levey (Chief, Division of Nephrology,have polymorphisms in cytokine genes been examined
New England Medical Center, Boston): You alluded toregarding susceptibility to HUS?
a therapy that could “clean up” the toxins from the whiteDr. King: That is an interesting question, given the
cells. Do you have any speculations on ways that thatpotential impact of these polymorphisms on the acute
might be done?inflammatory response. However, there are no data in
Dr. King: Leukopheresis would directly remove thepatients with HUS. This raises the larger question as to
toxin-coated white cells. Potentially, you could create anwhy only a minority of patients infected with STEC get
affinity column using Gb3 or another molecule with aHUS. Lingwood et al have raised the possibility that
Gal-Gal disaccharide. In most forms of acute renal fail-differences among individuals in the fatty acid composi-
ure in outpatients, we first see the patient two or threetion of the glycolipid receptor alter binding characteris-
days into the disease, when many cellular responsestics of Stx and thus susceptibility to its toxic effects [75].
might have occurred. Perhaps in the first 24 hours ofSupport for this hypothesis remains limited. I think it is
STEC infection there is a robust influx of polymorphonu-more compelling that the children with the most robust
clear cells in the glomerulus. What I find intriguing aboutevidence of systemic inflammation appear to be those
the report of te Loo et al was that even days after presen-at greater risk. I suspect those are the children who have
tation there was evidence of toxin-bearing polymorpho-greater movement of toxin into the circulation (a higher
nuclear cells in the blood [45]. This finding would imply
dosage of Stx) and higher concentrations of pro-inflam-
ongoing endothelial cell injury early in the hospitaliza-
matory cytokines making target organs more vulnerable. tion and a potential therapeutic window of opportunity
Dr. Madias: What do we know about the mechanism for us to lessen the toxin exposure.
of binding of Shiga toxin to polymorphonuclear cells? Dr. Madias: Could you please address other therapeu-
Dr. King: These recent data are based on two reports tic approaches, such as Shiga toxin binding residue to
[45, 50]. The nature of the receptor is unclear; however, prevent absorption of toxin, hyperimmune antitoxin an-
it is not Gb3. tiserum, and Shiga toxin receptor antagonists? Also,
Dr. John T. Harrington (Dean, Tufts University would you comment on the utility of antibiotic treatment
School of Medicine, Boston): You told us that 70% of of enterohemorrhagic E. coli?
the cases of HUS are related to O157:H7. Do we know Dr. King: A large clinical trial using a product named
whether the residual 30% of E. coli share the same char- “Synsorb” was recently halted. It is a form of dirt that
acteristics? bears the receptor for toxin that is ingested, binds the
Dr. King: A large number of serotypes of E. coli are toxin, and lowers the concentration of toxin within the
capable of producing Stx1 and Stx2. To my knowledge, gut. The jury is out on the specifics of the trial. Also,
the serotype is not a major factor in determining the newer carbohydrate ligands have been reported that ef-
relative risk of acquiring HUS. However, it appears that fectively bind the toxin and could potentially be used
the majority of patients with HUS have STEC that pro- therapeutically in the future. Antibiotic therapy remains
duce Stx2. Thus, this subtype probably is more likely to somewhat controversial, yet some very important data
induce systemic disease. suggest that ciprofloxacin actually increases production
Dr. Harrington: Andy, you said that “cleaving prote- of the Shiga toxin. I think at this time the use of antibiot-
ase activity” was normal in HUS but absent in TTP, yet ics is best avoided.
we see the same pathologic findings in both diseases. Dr. Lawrence Milner (Chief, Division of Pediatric
How do you account for that discrepancy? Nephrology, Floating Hospital for Infants and Children,
Dr. King: I think that thrombotic microangiopathies New England Medical Center): You mentioned that pa-
are diseases associated with endothelial cell injury. Per- tients with E. coli O15:H7 with a higher white cell count
sons with rare forms of recurrent TTP are not in a state have a worse prognosis. You also demonstrated a mecha-
of unrelenting thrombotic microangiography. Thus there nism of transportation of toxin in the body by white cells.
must be an additional provocateur triggering the re- Are children with the higher white cell count at greater
sponse. The deficiency in cleaving protease activity in risk because they have more toxin being delivered to
these patients makes them susceptible to the full expres- the kidneys, or is it the high white cell numbers arriving
at the kidney that are causing the damage?sion of microvascular disease. I managed a woman with
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Dr. King: My answer has to be purely speculative; serum creatinine level, proteinuria, or hematuria. I sus-
pect that the majority of these children have subclinicalhowever, the association of leukocytosis with a poor
outcome is well documented. I would guess that the neurologic involvement. The small number of children
who die are frequently those with severe neurologicdegree of leukocytes is a reflection of the magnitude of
bowel disease, and that the greater the gut inflammation, involvement.
Dr. Modi: Besides E. coli, what are the other infec-the greater the influx of Shiga toxin. The parent com-
pound of this family of toxins comes from Shigella dysent- tious causes of HUS? Does the pathogenesis in these
cases involve Shiga-toxin-like substances?eriae. Although we in the United States don’t see Shigella
dysenteriae very often, it is a violent disease that has Dr. King: A variety of infections are associated with
thrombotic microangiopathies other than E. coli and Shi-much more hemorrhagic colitis and bowel wall inflam-
mation. gella, most notably HIV. Furthermore, rarely other en-
teric gram-negative rods can express Shiga toxins.Dr. Dana Miskulin (Nephrology Fellow, New En-
gland Medical Center): Have any in-vitro studies shown Dr. Ronald D. Perrone (Division of Nephrology,
New England Medical Center): I found the hypothesisthat the Shiga toxin itself causes lymphocyte degranu-
lation? that polymorphonuclear cells carry the Shiga toxin to
the glomerulus very interesting. Are there experimentalDr. King: Little is known of the effects of Stx on
lymphocytes. It is noteworthy that the B subunit can models with cytokines in animals in situ?
Dr. King: Shiga toxin has been infused into a varietyinduce apoptosis in B lymphocytes. Our finding that Stx
induces oxidative burst in PMNs was the first in-vitro of species with differing responses. Perhaps the baboon
is one of the most relevant models, and on a recent visitevidence of PMN oxidative burst triggered by Stx. As I
alluded to earlier, data are conflicting regarding the di- to Utah I suggested that Dr. Seigler admix blood and
Stx prior to infusion. Potentially, the carrier cell mightrect effects of toxin on monocytes/macrophages. Tesh
et al clearly found that there was an increase in IL-1 be a critical determinant of target organ injury.
Dr. V. Balakrishnan (Division of Nephrology, Newproduction [39].
Dr. Bertrand L. Jaber (Division of Nephrology, New England Medical Center, Boston): I still have some con-
ceptual problems with the neutrophils. These cells seemEngland Medical Center): Since Shiga toxin binds to cir-
culating leukocytes, which can be detected by immuno- to be the least suited to be transporters of toxin. Your
lab has shown that Shiga toxin is a potent activator offluorescence, do you envision the commercialization of
this assay for early detection of the hemolytic-uremic neutrophils. I find it difficult to accept that these acti-
vated neutrophils can migrate beyond the microvascula-syndrome?
Dr. King: I think detection of Stx bound to PMNs ture, as they are likely to be adherent to the endothelium.
You showed some autopsy data that reported approxi-should be relatively straightforward. This could be
achieved using standard FACS analysis with appropri- mately 900 neutrophils per 100 glomeruli [63]. Given this
low ratio of neutrophils to glomeruli, it is difficult toate immunofluorescent probes.
Dr. Gopesh K. Modi (Nephrology Fellow, New Eng- postulate a role for significant neutrophil-induced endo-
thelial injury in this disease.land Medical Center): What is the normal function of Gb3
receptors in the body? The density of these receptors is Dr. King: I suspect that the movement of PMNs into
the lamina propria generates a local inflammatory re-high in the kidneys. What is the density of these receptors
in the central nervous system, and does it correlate with sponse disrupting barrier function of the intestinal wall
and leading to movement of toxin into the circulationthe relative absence of neurologic involvement in diar-
rhea-associated HUS? and thus, exposure of the circulating cells. I think it is
very unlikely that the cells move in and out of the laminaDr. King: The natural role of Gb3 in cell function is
unknown. The richest source of Gb3 is the cortical tubu- propria. I think the cells are firmly attached to various
adhesion molecules.lar cell. However, the renal vasculature and mesangial
cells also express the glycolipid. The brain is another Regarding the small number of PMN cells in the glo-
meruli found in autopsy specimens, there are severalabundant source of Gb3, but I suspect that the kidney
is more vulnerable to injury for several reasons. The potential explanations. First, it is possible that unbound
or “free” toxin in the plasma causes direct injury to theglomerular microvasculature is distinctive because of its
high flow rates, hydraulic permeability, and pressure. glomerular cell and the tubular cell, that is, the PMN
plays no role in injury. Second, the PMN might functionHigh blood flow rates directly increase local shear stress,
and ultrafiltration increases shear stress by increasing as a carrier for toxin with transfer from the lower affinity
binding site on the PMN to the higher affinity Gb3 onviscosity within the glomerular capillary. Higher shear
stress tends to increase platelet binding and activation. the target cell. This possibility does not implicate the
PMN in the tissue injury. The third possibility is that aIt’s a lot harder to quantitate neurologic injury than renal
injury. There’s no obvious quantifiable marker, such as binding event occurs, toxin is delivered to the target,
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and the PMN contributes to cell injury either by release mains relatively uncommon, and thus a child might never
be exposed again. Children with E. coli also generateof reactive oxygen species, proteases, or phospholipids.
When you analyze autopsy specimens, by definition the antibodies to specific components of the bacterial lipo-
polysaccharide, which might afford protection from fu-children have died of the disease. The timing of death
is usually about one week into the hospitalization and ture infection. It is clear that there are patients with
recurrent TTP or HUS, the pathogenesis of which hasthus the glomerular disease might have passed through
several phases. been established for some of these patients, for example,
those with defective vWF cleaving protease activity orDr. Balakrishnan: Most of the pathologic data indi-
cate endothelial swelling and separation from the base- Factor H deficiency. However, I am unaware of data
confirming whether children with E. coli-induced HUSment membrane. Most of the data that we have seen
describe apoptosis, a very controlled form of cell death. are protected from subsequent exposures.
Dr. Harrington: Has the disease decreased in inci-Dr. King: There is only one report that Shiga toxins
induce apoptosis in glomerular endothelial cells [76]. dence since 1993? Did the new public health regulations
make any difference?Whether apoptosis plays a dominant role in the glomeru-
lar injury is speculative. As you alluded to, the most Dr. King: The disease is increasing in frequency and
has been labeled as an emerging pathogen by the CDC.common histologic manifestation is endothelial swelling
and uplifting from the basement membrane, not the typi- Dr. Harrington: Why don’t we just cook the ham-
burgers?cal findings of apoptosis. I suspect that this is a manifesta-
tion of direct toxicity of Stx on the glomerular endothe- Dr. King: There are no rare hamburgers in our house.
Nothing pink!lial cell. It’s interesting to note in the studies by Forsyth
et al that PMNs obtained from children with HUS caused
Reprint requests to Dr. A. King, Division Head, Scripps Clinic, Divi-
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nia, 92037, USA.thelial cells [57]. I think these cells are injured in ways
E-mail: Aking@Scrippsclinic.comother than just apoptosis. Although apoptosis might not
be a dominant feature in glomerular injury, more evi-
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